Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cognition - Other Clear all
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing

NCT01602263
View directory record Official record
Conditions
Aphasia, Autism, Schizophrenia
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851
View directory record Official record
Conditions
Schizophrenia, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Glendale, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCT02832037
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Garden Grove, California • Lemon Grove, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Not applicable Interventional Results available

Oxytocin Treatment of Schizophrenia

NCT01028677
View directory record Official record
Conditions
Paranoia, Schizophrenia, Schizoaffective Disorder
Interventions
intranasal spray with oxytocin, nasal spray without oxytocin
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 4, 2026, 1:49 PM EDT
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

NCT01009060
View directory record Official record
Conditions
Schizophrenia
Interventions
GSK239512, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Garden Grove, California • Los Angeles, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional

SB-773812 Administered In Adults With Schizophrenia

NCT00259870
View directory record Official record
Conditions
Schizophrenia
Interventions
SB-773812, Olanzapine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 4 Interventional

Target Engagement and Response to Oxytocin

NCT03245437
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin nasal spray, Social Cognition Skills Training, Health Management, Placebo nasal spray
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 4 Interventional

A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia

NCT00573417
View directory record Official record
Conditions
Schizophrenia
Interventions
modafinil, Placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional

Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults

NCT01422902
View directory record Official record
Conditions
Schizophrenia
Interventions
Plasticity-based Cognitive Training, Non-plasticity-based Training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 4, 2026, 1:49 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

NCT02654405
View directory record Official record
Conditions
Schizophrenic Disorders, Cognitive Function
Interventions
Sodium Butyrate, Placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Not applicable Interventional

Can Cognitive Training Decrease Reactive Aggression?

NCT03623477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Impulsive Aggression, Emotion, Impulsivity
Interventions
Cognitive Remediation (CRT), CRT+ Social Cognition Training
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Modafinil Effects on Cognition in Schizophrenia Patients

NCT00711464
View directory record Official record
Conditions
Schizophrenia
Interventions
modafinil (M1, M2, M4)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 4 Interventional

Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

NCT00488163
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Brentwood, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 4, 2026, 1:49 PM EDT
Terminated Phase 2 Interventional Results available

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756
View directory record Official record
Conditions
Schizophrenia
Interventions
LY500307 150mg, LY500307 75mg, Placebo, LY500307 25mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 3 Interventional

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

NCT00654706
View directory record Official record
Conditions
Schizophrenia, Cognition
Interventions
Sertindole, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
26
States / cities
Garden Grove, California • National City, California • Pasadena, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 4, 2026, 1:49 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

NCT02710097
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active inhaled cannabis, Placebo, Active Oral Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Not applicable Interventional Results available

Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia

NCT01891721
View directory record Official record
Conditions
Schizophrenia
Interventions
Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Not applicable Interventional

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

NCT02459210
View directory record Official record
Conditions
Psychosis
Interventions
CLUES, therapy and computer games
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 4, 2026, 1:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

NCT00211380
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 4, 2026, 1:49 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Social Cognition in Schizophrenia

NCT00884897
View directory record Official record
Conditions
Social Cognition, Social Anxiety, Emotional Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 4, 2026, 1:49 PM EDT